Policy & advocacy
Our mandate
EHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders. It is informed by additional expertise drawn from our scientific and clinical networks. Alignment and collaboration with patient organizations and other stakeholders are key.
Every four to five years, EHA lays down its views and advocacy goals on topics of key importance to its members in a series of position papers. Four were published in HemaSphere in 2020:
- EHA position paper on affordable access to OMPs
- EHA position paper on fair pricing of innovative medicines
- EHA position paper on precision diagnostics
- EHA position paper on personalized hedicine
What we do
European Affairs monitors policy development and engages with EU lawmakers to ensure that current and upcoming legislation reflects the needs and concerns of hematology professionals across Europe. We actively seek alignment and collaboration with other stakeholders.
Examples of our work
Implementation of the Clinical Trials Regulation (CTR)
Revision of the Substances of Human Origin (SoHO) legislation
EU Health Technology Assessment Regulation (HTAR)
European Health Data Space legislation
Implementation of the In Vitro Diagnostic medical devices Regulation (IVDR)
Back